Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A PHASE 1/2, OPEN-LABEL, MULTICENTER STUDY TO EVALUATE A DOSING REGIMEN WITH TWO STEP-UP PRIMING DOSES AND LONGER DOSING INTERVALS OF ELRANATAMAB (PF-06863135) MONOTHERAPY IN PARTICIPANTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

Next Previous
X
Search
Trial Profile

A PHASE 1/2, OPEN-LABEL, MULTICENTER STUDY TO EVALUATE A DOSING REGIMEN WITH TWO STEP-UP PRIMING DOSES AND LONGER DOSING INTERVALS OF ELRANATAMAB (PF-06863135) MONOTHERAPY IN PARTICIPANTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 29 Nov 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Elranatamab (Primary)
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Acronyms MagnetisMM-9
  • Sponsors Pfizer

    • Most Recent Events

    • 04 Jun 2024 Results evaluating cytokine release syndrome (CRS) in patients with relapsed or refractory multiple myeloma receiving step-up priming doses and longer dosing intervals of elranatamab, presented at the 60th Annual Meeting of the American Society of Clinical Oncology.
    • 29 Apr 2024 According to Pfizer media release, data from this trial will be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
    • 21 Feb 2024 Dexamethasone has been removed from the study, hence number of treatment arms has been changed to 4.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top